PENZBERG, Germany--(BUSINESS WIRE)--The peroxisome proliferator-activated receptors (PPAR a, ß/d and ?) are nuclear receptors that modulate transcription of regulatory pathways involved in diseases ranging from metabolic syndrome to cancer. They therefore hold great potential as therapeutic targets for the treatment and prevention of disease. PPAR ß/d activation has been reported to increase fatty acid catabolism, ameliorate insulin resistance and decrease serum glucose, implicating a potential significance as a target in the treatment of type 2 diabetes. However, this is clouded by controversial reports on the role of PPAR ß/d in cancer, with some reports suggesting that its activation potentiates tumorigenesis while others suggest that cell proliferation is either unaffected or inhibited by PPAR ß/d activation.
